SEC Form 4 · accession 0001232524-15-000120

Jazz Pharmaceuticals plc · JAZZ

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, Europe and Rest of World

Period of report

May 26, 2015

Accepted (ET)

May 28, 2015 · 7:11 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001232524

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Ordinary Shares	May 26, 2015	M	5,834	$46.83	A	30,530	D
Ordinary Shares	May 26, 2015	M	1,500	$59.13	A	32,030	D
Ordinary Shares^F1	May 26, 2015	S	7,334	$179.4827	D	24,696	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F2	$46.83	May 26, 2015	M	5,834	D	—	Aug 8, 2022	Ordinary Shares	5,834	12,500	D
Non-Qualified Stock Option (right to buy)^F3	$59.13	May 26, 2015	M	1,500	D	—	Mar 4, 2023	Ordinary Shares	1,500	5,500	D

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.17 to $179.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F2Following the reported transaction, the remaining ordinary shares subject to this option vest in equal monthly installments from June 9, 2015 to August 9, 2016.
F3Following the reported transaction, the remaining ordinary shares subject to this option vest in equal monthly installments from June 5, 2015 to March 5, 2017.